Vanguard Group Inc. Raises Stock Position in OptimizeRx Co. (NASDAQ:OPRX)

Vanguard Group Inc. boosted its holdings in OptimizeRx Co. (NASDAQ:OPRX) by 0.6% in the first quarter, according to its most recent filing with the SEC. The institutional investor owned 1,027,293 shares of the company’s stock after buying an additional 6,291 shares during the period. Vanguard Group Inc. owned 5.65% of OptimizeRx worth $12,482,000 as of its most recent SEC filing.

Other institutional investors have also bought and sold shares of the company. Nisa Investment Advisors LLC increased its stake in OptimizeRx by 215.0% in the 4th quarter. Nisa Investment Advisors LLC now owns 2,142 shares of the company’s stock worth $31,000 after buying an additional 1,462 shares in the last quarter. Cetera Trust Company N.A purchased a new stake in OptimizeRx in the 4th quarter worth $77,000. Hillsdale Investment Management Inc. purchased a new stake in OptimizeRx in the 4th quarter worth $225,000. BNP Paribas Financial Markets grew its position in shares of OptimizeRx by 283.6% during the first quarter. BNP Paribas Financial Markets now owns 27,910 shares of the company’s stock valued at $339,000 after purchasing an additional 20,634 shares in the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. purchased a new position in shares of OptimizeRx during the first quarter valued at about $542,000. Hedge funds and other institutional investors own 76.47% of the company’s stock.

Analyst Ratings Changes

A number of research analysts have recently weighed in on OPRX shares. Barclays cut their price objective on OptimizeRx from $15.00 to $11.00 and set an “equal weight” rating for the company in a research report on Monday. JMP Securities restated a “market outperform” rating and set a $16.00 price objective on shares of OptimizeRx in a research report on Friday, June 21st. B. Riley began coverage on OptimizeRx in a research report on Thursday, July 25th. They set a “buy” rating and a $18.50 price objective for the company. Finally, Stifel Nicolaus reaffirmed a “buy” rating and issued a $13.00 price target on shares of OptimizeRx in a report on Wednesday, May 15th. One investment analyst has rated the stock with a hold rating and six have assigned a buy rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $15.50.

OptimizeRx Trading Up 3.7 %

Shares of NASDAQ OPRX opened at $8.65 on Wednesday. The business’s 50 day moving average is $10.26 and its two-hundred day moving average is $11.85. The company has a debt-to-equity ratio of 0.26, a current ratio of 2.88 and a quick ratio of 2.88. OptimizeRx Co. has a 1-year low of $6.92 and a 1-year high of $16.65. The stock has a market capitalization of $158.04 million, a P/E ratio of -8.48 and a beta of 1.26.

OptimizeRx (NASDAQ:OPRX) last announced its earnings results on Tuesday, May 14th. The company reported ($0.27) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.11) by ($0.16). OptimizeRx had a negative net margin of 23.10% and a negative return on equity of 6.96%. The business had revenue of $19.69 million for the quarter, compared to analysts’ expectations of $18.66 million. During the same quarter last year, the firm earned ($0.34) EPS. As a group, research analysts expect that OptimizeRx Co. will post -0.46 EPS for the current year.

OptimizeRx Company Profile

OptimizeRx Corporation, a digital health technology company, enables care-focused engagement between life sciences organizations, healthcare providers, and patients at critical junctures throughout the patient care journey. It offers various tech-enabled marketing solutions through its Artificial Intelligence-generated Dynamic Audience and Activation Platform, which enables customers to execute traditional marketing campaigns on its proprietary digital point-of-care network, as well as dynamic marketing campaigns that optimize audiences in real time to increase the value of treatment information for healthcare professionals and patients in response to clinical care events.